The Implantation Under Echography of Fiducial Markers in the Intraprostatic Lesion and Prostate
Launched by UNIVERSITY HOSPITAL, GHENT · Feb 10, 2009
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • histological proven adenocarcinoma of the prostate
- • T1-T4 tumors
- • Radiotherapy as primary therapy +/- androgen deprivation
- • Presence of an intraprostatic lesion (IPL) on MRI/MRS
- • Presence of an intraprostatic lesion (IPL) on ultrasound
- • WHO 0-2
- Exclusion Criteria:
- • Other primary tumor, except non-melanoma skin cancer
- • No written informed consent
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ghent, , Belgium
Patients applied
Trial Officials
Gert De Meerleer, MD, PhD
Principal Investigator
University Hospital, Ghent
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials